265 | IMPACT OF IGHV REPERTOIRE AFTER IBRUTINIB‐CONTAINING REGIMENS IN YOUNGER UNTREATED MCL PATIENTS: AN ANALYSIS OF THE TRIANGLE DATA EMBEDDED IN THE MULTIPLY PROJECT

Le résumé fourni par la source

response rate (ORR).Secondary endpoints were best complete response rate (CRR), progression free-survival (PFS), overall survival (OS) and safety.Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were graded according to the ASTCT 2019 criteria.Hematological toxicity and infections were graded according to NCI CTCAE (version 5.0).Results: Between February 2023 and July 2024, 12 patients with R/R transformed WM were treated with BsAb (6 glofitamab and 6 epcoritamab).Median age at WM diagnosis was 72 years (range 43-83).Patients received a median of 1 prior line of treatment (range, 0-6) for WM, including 4 treated with a BTK inhibitor (2 with ibrutinib, 1 with zanubritinib and 1 received both successively).4 patients had concurrent diagnosis of WM and DLBCL.For the others, the median time from WM to HT was 5.3 years (range, 0.4-12.8)and 15 months (range, 1-48) from HT diagnosis to BsAb.Patients had received a median of 2 prior lines (range, 1-5) for HT.Five patients were previously treated with CAR T-cell, including 2 with prior ASCT.At the time of BsAb, 75% of patients were refractory to the last treatment, and 67% to at least 2 consecutive lines.The median age was 80 years (range, 45-86).Patient treated with glofitamab had received a median of 9 cycles (6-12) and those treated with epcoritamab a median of 3 cycles (2-6).Best ORR was 92% and best CRR was 42%.CRS occurred in 10 patients (83%, with only 1 grade 3) and ICANS in 2 patients (17%, no grade 3-4).Seven patients (58%) presented infections, including 4 grade 3.After a median follow-up of 9.4 months (95% CI: 4-23), the 6-months PFS and OS were 57% (95% CI: 34%-94%) and 75% (95% CI: 54%-100%), respectively.Five deaths were reported, 3 due to disease progression and 2 from infection.Conclusion: This study shows an interesting efficacy of CD3xCD20 BsAb in R/R transformed WM in a population of elderly and heavily pre-treated patients, without unexpected toxicity.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.